Knee osteoarthritis is a common disease troubling middle-aged and elderly people. Mesenchymal stem cell joint injection, as a regenerative medicine therapy, is providing a new option for patients with early to mid-stage knee osteoarthritis to relieve pain and delay surgery.
Treatment principle and goals
Mesenchymal stem cells have immunomodulatory and tissue repair capabilities. When injected into the joint cavity, they reduce inflammation and promote cartilage repair, thereby relieving pain and improving joint function. Treatment mainly targets early to mid-stage patients, aiming to delay replacement surgery and preserve the patient's own joint.
Treatment plan
The plan usually combines rehabilitation exercise and weight management to consolidate results. The number and interval of injections vary with individual conditions, and most patients can gradually resume daily activities after treatment.
Suitable population
Suitable for patients with early to mid-stage cartilage wear shown on imaging, poor response to conservative treatment, and who wish to avoid or postpone surgery. Patients can undergo imaging grading and cell preparation evaluation at partner hospitals.
MedBridge services
Full course and cost details can be learned through cost estimation, and patients can also book remote consultation for initial evaluation. MedBridge will assist in arranging evaluation and treatment at partner hospitals.